H.C. Wainwright Thinks Bioxcel Therapeutics’ Stock is Going to Recover

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Bioxcel Therapeutics (BTAI), with a price target of $176.00. The company’s shares closed last Friday at $33.03, close to its 52-week low of $28.00.

According to TipRanks.com, Selvaraju is a 4-star analyst with an average return of 6.5% and a 47.0% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Protalix Biotherapeutics, EyePoint Pharmaceuticals, and Bausch Health Companies.

Bioxcel Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $101.17, a 199.7% upside from current levels. In a report issued on May 28, UBS also maintained a Buy rating on the stock with a $92.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $71.50 and a one-year low of $28.00. Currently, Bioxcel Therapeutics has an average volume of 421K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focuses on drug development. The firm’s two clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts